首页> 外文期刊>Diabetes >Novel IncRNA Erbb4-IR Promotes Diabetic Kidney Injury in db/db Mice by Targeting miR-29b
【24h】

Novel IncRNA Erbb4-IR Promotes Diabetic Kidney Injury in db/db Mice by Targeting miR-29b

机译:新型IncRNA Erbb4-IR通过靶向miR-29b促进db / db小鼠的糖尿病肾损伤

获取原文
获取原文并翻译 | 示例
       

摘要

Transforming growth factor-p/Smad signaling plays an important role in diabetic nephropathy. The current study identified a novel Smad3-dependent long noncoding RNA (IncRNA) Erbb4-IR in the development of type 2 diabetic nephropathy (T2DN) in db/db mice. We found that Erbb4-IR was highly expressed in T2DN of db/db mice and specifically induced by advanced glycosylation end products (AGEs) via a Smad3-dependent mechanism. The functional role of Erbb4-IR in T2DN was revealed by kidney-specific silencing of Erbb4-IR to protect against the development of T2DN, such as elevated microalbuminuria, serum creatinine, and progressive renal fibrosis in db/db mice, and to block AGE-induced collagen I and IV expression in mouse mesangial cells (mMCs) and mouse tubular epithelial cells (mTECs). Mechanistically, we identified that the Erbb4-IR-microRNA (miR)-29b axis was a key mechanism of T2DN because Erbb4-IR was able to bind the 3' untranslated region of miR-29b genomic sequence to suppress miR-29b expression at transcriptional level. In contrast, silencing of renal Erbb4-IR increased miR-29b and therefore protected the kidney from progressive renal injury in db/db mice and prevented mTECs and mMCs from AGE-induced loss of miR-29b and f ibrotic response in vitro. Collectively, we identify that Erbb4-IR is a Smad3-dependent IncRNA that promotes renal fibrosis in T2DN by suppressing miR-29b. Targeting Erbb4-IR may represent a novel therapy for T2DN.
机译:转化生长因子-p / Smad信号在糖尿病肾病中起重要作用。当前的研究在db / db小鼠的2型糖尿病肾病(T2DN)的发展中确定了一种新型的Smad3依赖性长非编码RNA(IncRNA)Erbb4-IR。我们发现,Erbb4-IR在db / db小鼠的T2DN中高度表达,并通过Smad3依赖性机制被晚期糖基化终产物(AGEs)特异性诱导。肾特异性沉默Erbb4-IR可以保护Erbb4-IR免受T2DN的发展,例如升高的微量白蛋白尿,血清肌酐和db / db小鼠的进行性肾纤维化,并阻断AGE,从而揭示了Erbb4-IR在T2DN中的功能作用。 -诱导的胶原蛋白I和IV在小鼠肾小球系膜细胞(mMCs)和小鼠肾小管上皮细胞(mTECs)中的表达。从机制上讲,我们确定Erbb4-IR-microRNA(miR)-29b轴是T2DN的关键机制,因为Erbb4-IR能够结合miR-29b基因组序列的3'非翻译区来抑制miR-29b在转录时的表达水平。相反,沉默肾Erbb4-IR会增加miR-29b,从而保护肾脏免受db / db小鼠进行性肾损伤,并防止mTECs和mMCs受到AGE诱导的miR-29b损失和体外纤维化反应。总的来说,我们确定Erbb4-IR是Smad3依赖的IncRNA,通过抑制miR-29b促进T2DN中的肾纤维化。靶向Erbb4-IR可能代表T2DN的新疗法。

著录项

  • 来源
    《Diabetes》 |2018年第4期|731-744|共14页
  • 作者单位

    Department of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, CUHK-Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong SAR, China,Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China;

    Department of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, CUHK-Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong SAR, China,Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong SAR, China;

    Department of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, CUHK-Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong SAR, China,Department of Nephrology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China;

    Department of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, CUHK-Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong SAR, China;

    Department of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, CUHK-Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong SAR, China;

    Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China;

    Department of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, CUHK-Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong SAR, China;

    Department of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, CUHK-Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong SAR, China;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号